Protalix BioTherapeutics (NYSE:PLX) Rating Lowered to “Buy” at StockNews.com

StockNews.com downgraded shares of Protalix BioTherapeutics (NYSE:PLX) from a strong-buy rating to a buy rating in a research report report published on Monday.

Separately, HC Wainwright lifted their price target on Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd.

Protalix BioTherapeutics Stock Up 0.6%

NYSE:PLX opened at $1.67 on Monday. The business’s 50-day moving average price is $2.49 and its 200 day moving average price is $2.15. The firm has a market cap of $132.79 million, a P/E ratio of -12.85 and a beta of -0.05. Protalix BioTherapeutics has a 52-week low of $0.82 and a 52-week high of $3.10.

Protalix BioTherapeutics (NYSE:PLX) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.05) earnings per share for the quarter. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%. Sell-side analysts expect that Protalix BioTherapeutics will post 0.01 EPS for the current year.

Hedge Funds Weigh In On Protalix BioTherapeutics

A number of institutional investors have recently bought and sold shares of the stock. Y Intercept Hong Kong Ltd purchased a new position in Protalix BioTherapeutics during the 4th quarter valued at about $35,000. Marshall Wace LLP purchased a new position in Protalix BioTherapeutics during the 4th quarter valued at about $192,000. Renaissance Technologies LLC grew its stake in Protalix BioTherapeutics by 17.0% during the 4th quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company’s stock valued at $2,102,000 after acquiring an additional 162,100 shares in the last quarter. PFG Investments LLC purchased a new position in Protalix BioTherapeutics during the 4th quarter valued at about $39,000. Finally, Prudential Financial Inc. purchased a new position in Protalix BioTherapeutics during the 4th quarter valued at about $68,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.